Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols

Protocols

EDRN investigators protocols. The following is a list of the EDRN protocols that have been captured and curated. Additional information will be added as it is available. Contact information is provided as part of the detail for each protocol.

Contents

Title Abstract Investigator
Ecogenetic Study of Lung Cancer Spitz, Margaret R.
Establishment of a serum standard for use in high-throughput proteomic Semmes, John
Evaluating SelectMDx for the prediction of high-grade prostate cancer in men with low-grade prostate cancer on active surveillance in the Canary Prostate Active Surveillance Study (PASS) The need for repeated biopsy is a major downside of active surveillance, and can lead to patients opting for definitive treatment or, conversely, declining to ... Lin UW, Daniel W.
Expansion of Enduring Infrastructure to Support Lung Cancer Screening Research Schabath, Matthew
Expression based markers for breast cancer detection Marks, Jeffrey
GLNE 003: Preliminary Validation of Biomarkers Predictive of Barrett’s Esophagus Progression to Dysplasia and Adenocarcinoma    Recognizing that novel potential biomarkers are continually being identified and will need to be validated in a rapid, efficient, and scientifically ... Brenner, Dean
GSTP1 Methylation Sidransky, David
Glycoprotein Biomarkers for the Early Detection of Aggressive Prostate Cancer The Early Detection Research Network of the NCI is charged with the discovery, development and validation of biomarkers for early detection and prognosis ... Zhang, Hui L.
HNPCC colon cancer-associated SELDI mass spectrometry protein profiles in serum Lynch, Henry
Hepatocellular carcinoma Early Detection Strategy study Part 1: The first part of this study is to conduct follow-up for patients that were enrolled in the EDRN Phase 2 Validation Study called DCP (13). For this ... Marrero, Jorge
Hereditary Cancer Institute family study specimen bank Lynch, Henry
High-Throughput Evaluation of Breast Cancer Markers The objective of this study is to use a combination of AMT proteomics and ELISA microarray testing to discover and validate novel biomarkers for breast cancer. Zangar, Richard (Rick) C.
Hollingsworth - Aggressive vs Indolent 2012 Study Overview. We will examine DNA extracted from FFPE sections from approximately 200 different surgically resected primary pancreatic tumors from the UNMC ... Hollingsworth, Michael
Identification of New Markers in Normal and Abnormal Pap Smears Unger, Elizabeth R.
Identification of biomarkers for ER+ breast cancer Validate clinically useful early detection biomarkers specific to ER+ breast cancer Li, Christopher
Identification of biomarkers for lung cancer in never smokers The overall goal of this project is to identify, verify and apply biomarkers for the early diagnosis or risk assessment of lung cancer in never smokers. The ... Gazdar, Adi
Identification of protein and genetic biomarkers of prostate cancer and risk factors for progression of disease Purpose/Objectives To collect biological samples from subjects with prostate cancer to improve the accuracy of screening tests, identify markers that will ... Leach, Robin J
Inflammation as a Potential Marker of Risk ad Progression for Prostate Cancer Leach, Robin J
Integrated Development of Novel Molecular Markers Sidransky, David
Intergrated Systems Biology Approach for Ovarian Cancer Biomarker Discovery The overall objective is to validate serum protein markers for early diagnosis of ovarian cancer with the ultimate goal being to develop a multiparametric ... Diamandis, Eleftherios P.
Light Scattering Spectroscopy for the Detection of Colorectal Neoplasia Lynch, Henry
Liver Full Reference Set Application :Timothy Block - Drexel Univ (2010) The goal of this application is to determine if the levels of serum GP73 and fucosylated kininogen/acute phase proteins can be used to detect hepatocellular ... Block, Timothy
Liver Full Reference Set Application: David Lubman - Univ of Michigan (2011) In this work we will perform the next step in the biomarker development and validation. This step will be the Phase 2 validation of glycoproteins that have ... Lubman, David
Liver Full Reference Set Application: Hiro Yamada - Wako (2011) Wako has received new 510(k) clearance for Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) and Des-gamma-carboxy prothrombin (DCP) ... Yamada, Hiro
Liver Rapid Reference Set Application ( #2): Lubman - Univ of Michigan (2010) We are requesting the reference set, which includes 50 HCC cases and 50 cirrhotic controls. In our preliminary study, AFP had a AUROC of 0.66 while the AUROC ... Lubman, David
Liver Rapid Reference Set Application (#1): David Lubman - Univ of Michigan (2009) We are requesting the reference set, which includes 50 HCC cases and 50 cirrhotic controls. In our preliminary study, AFP had a AUROC of 0.66 while the AUROC ... Lubman, David
Liver Rapid Reference Set Application (#1): Laura Beretta-FHCRC (2011) Test 2 candidate biomarkers for early detection of HCC. Marker S and Marker L. Beretta, Laura
Liver Rapid Reference Set Application (#2): Laura Beretta-FHCRC (2011) Test 2 candidate biomarkers for early detection of HCC. Marker S and Marker L. Beretta, Laura
Liver Rapid Reference Set Application: Gary Norman-INOVA (2012) We have developed a new and novel assay for the detection of Golgi protein 73 (GP73), also known as Golgi membrane protein 1 (Golm1) or Golgi phosphoprotein 2 ... Norman, Gary L.
Liver Rapid Reference Set Application: Gianluigi Giannelli - Univ of Bari (2008) To evaluate biomarker performance in an out-side cohort of LC and HCC patients Giannelli, Gianluigi
Announcement 10/23/2017

Three new FOAs on the Human Tumor Atlas and associated with the Cancer Moonshot Initiative have been released. Please click here for more information.

32nd SC Meeting
Thank you to everyone who made the 32nd EDRN Steering Committee meeting a success. The next event is the 10th EDRN Scientific Workshop from March 6-8, 2018 in Bethesda, MD. More information about this Workshop will be sent soon. Click here to view the flyer.
EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.